PD-L1 inhibitor + SHR0302

**PD-L1 inhibitor + SHR0302** is an experimental combination therapy evaluated for the treatment of cancers, particularly non-small cell lung cancer (NSCLC), including patients who are either treatment-naïve or have acquired resistance to immunotherapy[1][3][6][10]. The combination brings together a **PD-L1 inhibitor**, an immune checkpoint inhibitor that blocks the interaction between programmed death-ligand 1 (PD-L1) on tumor cells and its receptor on T cells to restore anti-tumor immune responses, and **SHR0302**, a highly selective small molecule inhibitor of Janus kinase 1 (JAK1)[2][4]. SHR0302 modulates immune and inflammatory pathways by selectively blocking the JAK1-mediated signaling, potentially reducing immune suppression and enhancing the efficacy of checkpoint blockade. Preclinical and early clinical research suggests that this combination may address resistance mechanisms to immunotherapy by synergistically enhancing anti-tumor activity[3]. The combination is currently under investigation in phase II trials for NSCLC.

Other names

ivarmacitinib + adebrelimabSHR0302 + PD-L1 inhibitorPD-L1 inhibitor + SHR0302